Cecilia Jones - Jan 11, 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role: Chief Financial Officer
Signature: /s/ Andrea Paul, as Attorney-in-Fact
Stock symbol: LOGC
Transactions as of: Jan 11, 2022
Transactions value $: -$4,372
Form type: 4
Date filed: 1/13/2022, 05:36 PM
Next filing: Mar 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LOGC	Common Stock	Options Exercise		+5.94K			5.94K	Jan 11, 2022	Direct	F1
transaction	LOGC	Common Stock	Tax liability	-$4.37K	-2.18K	-36.62%	$2.01	3.76K	Jan 12, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LOGC	Restricted Stock Units	Options Exercise	$0	+5.94K		$0.00^*	0	Jan 11, 2022	Common Stock	5.94K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
F2	This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive.
F3	These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.

Remarks:

Exhibit List: Exhibit 24.1 Power of Attorney